Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Abatacept Stories

2014-02-24 08:29:54

SAN DIEGO, Feb. 24, 2014 /PRNewswire/ -- Ambrx Inc. today announced that Sheila Gujrathi, M.D., has joined its board of directors. Dr. Gujrathi is currently the chief medical officer at Receptos (Nasdaq: RCPT) where she is responsible for the clinical development of therapeutic candidates for the treatment of immune and metabolic diseases. "Sheila is an industry veteran with significant experience in immunologic and oncologic drug development," said Lawson Macartney, Ph.D., chief...

2013-10-24 12:26:15

EU5 Payers Agree that the Requirement for Direct Comparative Data Is Increasing in the Highly Competitive RA Market, According to a New Report from Decision Resources BURLINGTON, Mass., Oct. 24, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that results from the ADACTA trial, which showed that Roche's RoActemra is superior to AbbVie's Humira as a monotherapy in biologics-naive...

2013-10-10 08:26:50

Oral Agents Could Alter the Treatment Algorithm, After Establishing Clinical Profiles at Least Comparable to TNF-alpha Inhibitors, According to a New Report from Decision Resources BURLINGTON, Mass., Oct. 10, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the rheumatoid arthritis drug market will experience moderate growth over the next decade as sales increase from $12.3 billion in...

2013-09-24 11:22:59

In the U.S., there are nearly 300,000 children with juvenile arthritis and other rheumatic illnesses according to estimates from the American College of Rheumatology (ACR). For pediatric patients with systemic juvenile idiopathic arthritis (JIA), effective treatment for this disabling disease is imperative. New treatment recommendations that guide physicians caring for children with systemic JIA are now published in the ACR journals, Arthritis & Rheumatism and Arthritis Care &...

2013-09-19 08:29:40

Over Half of Xeljanz-Treated RA Patients Were Biologic Naive at Initiation, According to a New Report from BioTrends Research Group EXTON, Pa., Sept. 19, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that the vast majority of patients treated with Amgen's Enbrel and AbbVie's Humira--significantly more patients than those treated with any other nontraditional disease-modifying...

2013-06-14 08:25:32

PRINCETON, N.J. and NANJING, China, June 14, 2013 /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) and Simcere Pharmaceutical Group (NYSE: SCR), a leading pharmaceutical company in China, today announced that the companies have expanded their strategic relationship formed in 2010. The companies have agreed to collaborate in China on the development and commercialization of the subcutaneous (SC) formulation of Bristol-Myers Squibb's biologic medicine, Orencia® (abatacept), for the...

2013-06-11 20:23:46

PARIS, June 11, 2013 /PRNewswire/ -- AMPLE Study results highlighted during a press conference at the European League Against Rheumatism (EULAR) Annual congress - Year 2 data shows similar efficacy between ORENCIA plus methotrexate (MTX) and Humira plus MTX, consistent with the year 1 result which demonstrated comparable efficacy based on a non-inferiority endpoint for ACR 20 response - Radiographic...

2012-06-07 12:19:12

Safety of treatments was similar with fewer injection site reactions observed with abatacept Data from one of the few head-to-head trials in rheumatoid arthritis (RA) presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, demonstrates that at one year, 64.8% of patients receiving abatacept (Orencia) and 63.4% of patients receiving adalimumab (Humira) achieved ACR20. The Phase IIIb AMPLE study (Abatacept Versus Adalimumab Comparison in...

2012-05-14 02:27:41

PARIS, May 14, 2012 /PRNewswire/ -- - Results of head-to-head study comparing two biologic drugs on a background of methotrexate for the treatment of moderate to severe rheumatoid arthritis to be presented Bristol-Myers Squibb Company [http://www.bms.com ] (NYSE: BMY) today announced that the company will present 18 abstracts on abatacept at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology in Berlin,...

2011-06-08 11:07:00

NEW YORK, June 8, 2011 /PRNewswire/ -- One of the major annual rheumatology conferences, the European League Against Rheumatism's Congress (EULAR), was held May 25-28 in London. Citeline, Inc., reviewed the trends and highlights from clinical trial results reported at EULAR, noting that approved biologics in rheumatoid arthritis dominated the program, comprising roughly 25% of clinical trial abstracts presented. Updates from long-term trials for approved biologics in RA--including...